News | May 16, 2011

Frost & Sullivan Awards GE ‘Price Performance Value’ Leadership in PET Award

May 16, 2011 — GE Healthcare today received the Price Performance Value Leadership Award in PET (positron emission tomography) for North America 2011 from global research organization Frost & Sullivan.

According to Frost & Sullivan, the Price Performance Value Leadership Award is a prestigious recognition of GE Healthcare’s accomplishments in PET. Based on Frost & Sullivan’s analysis of the latest value-based systems currently being offering by PET/CT manufacturers, GE Healthcare’s Optima PET/CT 560 was found to offer a higher price performance value than any other system on the market.

First to the market with PET/CT in 2001, GE Healthcare has built upon its excellence in PET/CT with the Optima PET/CT 560, an innovative scanner designed to address the demands of today’s healthcare environment. Combining superb image quality, high productivity and a patient friendly experience, the Optima PET/CT 560 can continuously deliver ongoing value over time. The system offers efficiency and investment protection with the capability to grow with the future needs of the clinical practice. From the uninterrupted full head to toe exam to the remarkable dose reduction features, the Optima PET/CT 560 was designed to help physicians put patients’ needs first. It includes advanced VUE Point HD intelligent 3-D iterative reconstruction technique to enhance resolution for uncompromised image quality that can help enable clinicians to confidently detect small lesions and increase quantitative accuracy.

According to Frost & Sullivan, despite growing evidence pointing to its superior diagnostic capabilities in many applications within oncology and cardiology, PET/CT’s higher costs have been a deterrent to widespread adoption of this technology since its commercial introduction in 2001. Frost & Sullivan notes that the recent downturn in the U.S. economy and uncertainties surrounding healthcare reform further exasperated this challenge, as these circumstances intensified demand in the market for the more affordable imaging equipment that provides adequate performance in clinically relevant applications. Frost & Sullivan also notes the significant cost-barrier in PET/CT has prompted manufacturers of this technology to become more focused on developing systems that provide the highest performance at the lowest price point possible.

For more information: www.gehealthcare.com

Related Content

PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Novel PET Imaging Method Could Track and Guide Type 1 Diabetes Therapy
News | PET Imaging | August 03, 2018
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Overlay Init